Literature DB >> 2831244

Comparison of basal and adrenocorticotropin-stimulated plasma 21-deoxycortisol and 17-hydroxyprogesterone values as biological markers of late-onset adrenal hyperplasia.

J Fiet1, B Gueux, M Gourmelen, F Kuttenn, P Vexiau, P Couillin, M T Pham-Huu-Trung, J M Villette, M C Raux-Demay, H Galons.   

Abstract

Plasma 21-deoxycortisol (21-DOF) and 17-hydroxyprogesterone (17-OHP) concentrations were assayed before (basal) and 1 h after ACTH stimulation in 4 groups of normal subjects (35 follicular phase women, 22 luteal phase women, 33 adult men, and 15 prepubertal children) and in a group of 31 patients with the late-onset form of congenital adrenal hyperplasia (LOCAH) due to 21-hydroxylase deficiency as well as in 31 LOCAH) heterozygotes. The mean basal plasma 21-DOF concentrations in each of the 4 groups of normal subjects were between 8 ng/dL (0.23 nmol/L) and 11 ng/dL (0.31 nmol/L), and they increased significantly after ACTH stimulation to between 36 ng/dL (1.04 nmol/L) and 44 ng/dL (1.27 nmol/L). There were no differences in basal or ACTH-stimulated plasma 21-DOF levels in these 4 groups, whereas their basal and post-ACTH plasma 17-OHP levels did vary. Among the LOCAH patients, 83.8% had basal plasma 21-DOF levels and 61.2% had basal plasma 17-OHP levels higher than the highest basal 21-DOF [30 ng/dL (0.86 nmol/L)] and 17-OHP [450 ng/dL (13.61 nmol/L)] concentrations in the normal subjects, and all individual 21-DOF and 17-OHP levels after ACTH stimulation [greater than or equal to 404 ng/dL (11.67 nmol/L) and greater than or equal to 1040 ng/dL (31.47 nmol/L), respectively] were markedly higher than the highest 21-DOF [76 ng/dL (2.19 nmol/L)] and 17-OHP [580 ng/dL (17.55 nmol/L)] levels in the normal subjects. The mean post-ACTH/basal plasma level ratios among the LOCAH patients were 19.75 for 21-DOF and 8.03 for 17-OHP. In LOCAH heterozygotes, basal 21-DOF values were higher than normal in 48.3%, and post-ACTH values were higher than normal in 93.5% of the cases. In contrast, basal plasma 17-OHP levels were similar in LOCAH heterozygotes and normal subjects, and only 16.1% of the LOCAH heterozygotes had post-ACTH plasma 17-OHP levels higher than the highest normal value. If sex and phase of the menstrual cycle are taken into account, along with the incremental responses (post-ACTH minus baseline value) of plasma 21-DOF and 17-OHP, to compare LOCAH heterozygotes and normal subjects, the discriminating power for detection of heterozygocity was somewhat increased for 21-DOF (to 100%) and appreciably increased for 17-OHP (to 30%).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831244     DOI: 10.1210/jcem-66-4-659

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Zona fasciculata 21-hydroxysteroids and precursor-to-product ratios in 21-hydroxylase deficiency: further characterization of classic and non-classic patients and heterozygote carriers.

Authors:  F A Costa-Barbosa; V M Carvalho; O H Nakamura; T A S S Bachega; J G H Vieira; C E Kater
Journal:  J Endocrinol Invest       Date:  2010-10-04       Impact factor: 4.256

Review 2.  Non-classic adrenal hyperplasia in hyperandrogenism: a reappraisal.

Authors:  C Morán; E S Knochenhauer; R Azziz
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

3.  17-Hydroxyprogesterone response to ACTH in bilateral and monolateral adrenal incidentalomas.

Authors:  G P Bernini; G Brogi; M S Vivaldi; G F Argenio; M Sgrò; A Moretti; A Salvetti
Journal:  J Endocrinol Invest       Date:  1996-12       Impact factor: 4.256

4.  Structural and functional analysis of a novel mutation of CYP21B in a heterozygote carrier of 21-hydroxylase deficiency.

Authors:  Jörg Bojunga; Christoph Welsch; Iris Antes; Mario Albrecht; Thomas Lengauer; Stefan Zeuzem
Journal:  Hum Genet       Date:  2005-07-19       Impact factor: 4.132

5.  Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline.

Authors:  Phyllis W Speiser; Ricardo Azziz; Laurence S Baskin; Lucia Ghizzoni; Terry W Hensle; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; Victor M Montori; Sharon E Oberfield; Martin Ritzen; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2010-09       Impact factor: 5.958

Review 6.  Congenital Adrenal Hyperplasia.

Authors:  Selma Feldman Witchel
Journal:  J Pediatr Adolesc Gynecol       Date:  2017-04-24       Impact factor: 1.814

7.  Incidental adrenal nodules: association with exaggerated 17-hydroxyprogesterone response to adrenocorticotropic hormone.

Authors:  D B Turton; J T O'Brian; K M Shakir
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

8.  Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

Authors:  Phyllis W Speiser; Wiebke Arlt; Richard J Auchus; Laurence S Baskin; Gerard S Conway; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; M Hassan Murad; Sharon E Oberfield; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

9.  Analysis of a pitfall in congenital adrenal hyperplasia newborn screening: evidence of maternal use of corticoids detected on dried blood spot.

Authors:  Muriel Houang; Thao Nguyen-Khoa; Thibaut Eguether; Bettina Ribault; Séverine Brabant; Michel Polak; Irène Netchine; Antonin Lamazière
Journal:  Endocr Connect       Date:  2022-06-15       Impact factor: 3.221

10.  A Liquid Chromatography/Tandem Mass Spectometry Profile of 16 Serum Steroids, Including 21-Deoxycortisol and 21-Deoxycorticosterone, for Management of Congenital Adrenal Hyperplasia.

Authors:  Jean Fiet; Yves Le Bouc; Jérôme Guéchot; Nicolas Hélin; Marie-Anne Maubert; Dominique Farabos; Antonin Lamazière
Journal:  J Endocr Soc       Date:  2017-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.